Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anurag Relan

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|February 17, 2017
Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in AdolescentsJames W Baker, Avner Reshef, Dumitru Moldovan, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 17, 2011
Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedemaAnurag Relan, Kamran Bakhtiari, Edwin S van Amersfoort, et al.
British Journal of Clinical Pharmacology|April 19, 2013
Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedemaColm Farrell, Siobhan Hayes, Anurag Relan, et al.
The Journal of Allergy and Clinical Immunology|June 2, 2016
Angioedema attacks in patients with hereditary angioedema: Local manifestations of a systemic activation processZonne L M Hofman, Anurag Relan, Sacha Zeerleder, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 7, 2019
Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancyDumitru Moldovan, Jonathan A Bernstein, Roman Hakl, et al.
Clinical Drug Investigation|March 7, 2013
Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: evaluation of ige antibodiesC Erik Hack, Anurag Relan, Aartie Baboeram, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 29, 2013
Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label studyMarc A Riedl, Robyn J Levy, Daniel Suez, et al.
Advances in Therapy|June 18, 2026
Diverse Trial Designs, Populations, and Outcomes: A Systematic Literature Review of Trials for the Treatment of Hereditary Angioedema AttacksRaffi Tachdjian, Nihal Narsipur, Paranjoy Saharia, et al.
Clinical and Experimental Medicine|January 14, 2026
Patient-reported disease burden and health care utilization of HAE-nl-C1INH: insights from a real-world surveyDouglas Jones, Nihal Narsipur, Sally W Wade, et al.
The Journal of Allergy and Clinical Immunology|October 6, 2010
Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedemaBruce Zuraw, Marco Cicardi, Robyn J Levy, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
The Journal of Allergy and Clinical Immunology. in Practice|February 17, 2017
Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in AdolescentsJames W Baker, Avner Reshef, Dumitru Moldovan, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 17, 2011
Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedemaAnurag Relan, Kamran Bakhtiari, Edwin S van Amersfoort, et al.
British Journal of Clinical Pharmacology|April 19, 2013
Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedemaColm Farrell, Siobhan Hayes, Anurag Relan, et al.
The Journal of Allergy and Clinical Immunology|June 2, 2016
Angioedema attacks in patients with hereditary angioedema: Local manifestations of a systemic activation processZonne L M Hofman, Anurag Relan, Sacha Zeerleder, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 7, 2019
Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancyDumitru Moldovan, Jonathan A Bernstein, Roman Hakl, et al.
Clinical Drug Investigation|March 7, 2013
Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: evaluation of ige antibodiesC Erik Hack, Anurag Relan, Aartie Baboeram, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 29, 2013
Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label studyMarc A Riedl, Robyn J Levy, Daniel Suez, et al.
Advances in Therapy|June 18, 2026
Diverse Trial Designs, Populations, and Outcomes: A Systematic Literature Review of Trials for the Treatment of Hereditary Angioedema AttacksRaffi Tachdjian, Nihal Narsipur, Paranjoy Saharia, et al.
Clinical and Experimental Medicine|January 14, 2026
Patient-reported disease burden and health care utilization of HAE-nl-C1INH: insights from a real-world surveyDouglas Jones, Nihal Narsipur, Sally W Wade, et al.
The Journal of Allergy and Clinical Immunology|October 6, 2010
Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedemaBruce Zuraw, Marco Cicardi, Robyn J Levy, et al.
Pageof 4